An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology
An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology is a PHASE3 clinical asset sponsored by Lantheus Biosciences Ltd. in Alzheimer Disease. SEO and diligence focus: Florbetaben (BAY94-9172), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Alzheimer Disease
Modality: small molecule
Target: Florbetaben (BAY94-9172)
Sponsor: Lantheus Biosciences Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Florbetaben (BAY94-9172)
View original source fields
Condition raw: Alzheimer Disease
Condition normalized: Alzheimer Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Florbetaben (BAY94-9172)
Target normalized: Florbetaben (BAY94-9172)